

# Anti-RUNX1 Antibody

Rabbit polyclonal antibody to RUNX1 Catalog # AP59980

#### **Product Information**

Application WB, IF/IC, IHC
Primary Accession Q01196
Other Accession 003347

**Reactivity** Human, Mouse, Rat, Pig, Chicken

Host Rabbit
Clonality Polyclonal
Calculated MW 48737

#### **Additional Information**

Gene ID 861

Other Names AML1; CBFA2; Runt-related transcription factor 1; Acute myeloid leukemia 1

protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B;

PEBP2-alpha B; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV

core-binding factor alpha B subunit

**Target/Specificity** Recognizes endogenous levels of RUNX1 protein.

**Dilution** WB~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500)

IF/IC~~N/A IHC~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 -

1/500)

**Format** Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30%

glycerol, and 0.09% (W/V) sodium azide.

**Storage** Store at -20 °C.Stable for 12 months from date of receipt

#### **Protein Information**

Name RUNX1

**Synonyms** AML1, CBFA2

**Function** Forms the heterodimeric complex core-binding factor (CBF) with CBFB.

RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'- TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The

heterodimers bind to the core site of a number of enhancers and promoters,

including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis (PubMed: 17431401). Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter (PubMed: 10207087, PubMed: 14970218). Inhibits KAT6B-dependent transcriptional activation (By similarity). Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing (By similarity). Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells (PubMed: 17377532). Positively regulates the expression of RORC in T-helper 17 cells (By similarity).

**Cellular Location** 

Nucleus.


**Tissue Location** 

Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood


### **Background**

KLH-conjugated synthetic peptide encompassing a sequence within the center region of human RUNX1. The exact sequence is proprietary.

## **Images**




Western blot analysis of RUNX1 expression in MCF7 (A), Jurkat (B) whole cell lysates.



Immunohistochemical analysis of RUNX1 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

Immunofluorescent analysis of RUNX1 staining in THP1 cells. Formalin-fixed cells were permeabilized with 0.1%



Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.